Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Consolidated Net Income (2022 - 2026)

Orchestra BioMed Holdings has reported Consolidated Net Income over the past 5 years, most recently at -$22.9 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 22.08% to -$22.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$57.1 million through Mar 2026, up 13.87% year-over-year, with the annual reading at -$53.0 million for FY2025, 13.11% up from the prior year.
  • Consolidated Net Income was -$22.9 million for Q1 2026 at Orchestra BioMed Holdings, down from $6.0 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $6.0 million in Q4 2025 and troughed at -$22.9 million in Q1 2026.
  • The 5-year median for Consolidated Net Income is -$13.4 million (2024), against an average of -$12.9 million.
  • Year-over-year, Consolidated Net Income tumbled 125.14% in 2023 and then skyrocketed 137.08% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at -$9.8 million in 2022, then fell by 15.72% to -$11.4 million in 2023, then tumbled by 42.05% to -$16.2 million in 2024, then skyrocketed by 137.08% to $6.0 million in 2025, then crashed by 482.19% to -$22.9 million in 2026.
  • Per Business Quant, the three most recent readings for OBIO's Consolidated Net Income are -$22.9 million (Q1 2026), $6.0 million (Q4 2025), and -$20.8 million (Q3 2025).